menu
    • menu
    [{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Monomethyl Auristatin E","moa":"synthetic analogs of the dolastatin series","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MBrace Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"TPG Life Sciences Innovations","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Series B Financing","leadProduct":"Monomethyl Auristatin E","moa":"synthetic analogs of the dolastatin series","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ TPG Life Sciences Innovations","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ TPG Life Sciences Innovations"}]

    Find Clinical Drug Pipeline Developments & Deals for Monomethyl Auristatin E

    Menu

    Monomethyl Auristatin E

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MBrace Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MBrace Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monomethyl Auristatin E

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MBrace Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial Evaluating Investigationa...

                            Details : MBRC-101 (monomethyl auristatin E)is a novel, targeted ADC which targets the EphA5 receptor tyrosine kinase. It is under phase 1 clinical development for the treatment of multiple solid tumor cancers, including breast, non-small cell lung and other solid...

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 19, 2023

                            Lead Product(s) : Monomethyl Auristatin E

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MBrace Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MBrace Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monomethyl Auristatin E

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : TPG Life Sciences Innovations

                            Deal Size : $85.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody ...

                            Details : The financing will be used to support clinical development programs, including a first-in-human clinical trial of lead investigational ADC, MBRC-101, which targets the EphA5 receptor tyrosine kinase.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : Monomethyl Auristatin E

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : TPG Life Sciences Innovations

                            Deal Size : $85.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth